Immunotherapy and prostate cancer

Dendritic cells and the control of immunity

1998 • 14,345 citations

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

1994 • 7,043 citations

Structure and function of telomeres

1991 • 3,524 citations

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1991 • 3,493 citations

A survey of telomerase activity in human cancer

1997 • 2,747 citations

The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens

1987 • 2,403 citations

The Basic Science of Gene Therapy

1993 • 1,767 citations

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

1986 • 1,723 citations

Prostate-specific membrane antigen expression in normal and malignant human tissues.

1997 • 1,454 citations

Telomerase activity in human germline and embryonic tissues and cells

1996 • 1,345 citations

Immunity to Methylcholanthrene-Induced Sarcomas

1957 • 1,241 citations

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

1992 • 1,076 citations

Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?

1996 • 917 citations

Activation of telomerase in human lymphocytes and hematopoietic progenitor cells.

1995 • 871 citations

Purification of a Human Prostate Specific Antigen

2016 • 844 citations

Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor

1992 • 841 citations

Dominance and Crypticity of T Cell Antigenic Determinants

1993 • 838 citations

Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

1960 • 736 citations

Cytokine therapeutics: lessons from interferonalpha.

1994 • 703 citations

Heterogeneity of mucin gene expression in normal and neoplastic tissues.

1993 • 671 citations

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.

1990 • 628 citations

Identification of human cancers deficient in antigen processing.

1993 • 625 citations

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

2000 • 586 citations

Human prostate-specific antigen: structural and functional similarity with serine proteases.

1986 • 580 citations

The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes

1999 • 574 citations

Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro

1995 • 569 citations

Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

2001 • 566 citations

PURIFICATION OF HUMAN PROSTATE SPECIFIC ANTIGEN

1979 • 547 citations

Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.

1993 • 510 citations

Dendritic Cell Vaccines for Cancer Immunotherapy

1999 • 497 citations

Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells

1996 • 495 citations

Tumor Therapy with Targeted Atomic Nanogenerators

2001 • 483 citations

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

1999 • 468 citations

IL-15: A Pleiotropic Cytokine with Diverse Receptor/Signaling Pathways Whose Expression Is Controlled at Multiple Levels

1996 • 459 citations

Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver

1989 • 459 citations

Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

1990 • 414 citations

A potential role for interleukin-15 in the regulation of human natural killer cell survival.

1997 • 413 citations

Vaccinia Virus: A Tool for Research and Vaccine Development

1991 • 410 citations

Molecular cloning of human prostate specific antigen cDNA

1987 • 399 citations

Structure of Peptides Associated with Class I and Class II MHC Molecules

1994 • 381 citations

Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor

1992 • 364 citations

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

2000 • 355 citations

Telomerase and differentiation in multicellular organisms: Turn it off, turn it on, and turn it off again

2002 • 345 citations

Telomerase: A target for cancer therapeutics

2002 • 331 citations

Sleeping Beauty , a wide host-range transposon vector for genetic transformation in vertebrates 1 1Edited by J. Karn

2000 • 324 citations

Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice.

1992 • 303 citations

Stabilized plasmid-lipid particles: construction and characterization

1999 • 296 citations

In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen

1997 • 267 citations

Cytotoxic T cell immunity against telomerase reverse transcriptase in humans

2000 • 259 citations

Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man

1999 • 253 citations

Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer

1995 • 240 citations

Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis.

1996 • 232 citations

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer

2002 • 230 citations

Dendritic cells: a link between innate and adaptive immunity.

1999 • 228 citations

The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.

1999 • 219 citations

Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.

1999 • 218 citations

TAP off - tumors on

1997 • 215 citations

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

1994 • 214 citations

Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization.

1997 • 210 citations

Induction of anti-self-immunity to cure cancer

1995 • 207 citations

The use of DNA viruses as vectors for gene therapy.

1994 • 206 citations

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

2001 • 198 citations

Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment

1999 • 191 citations

Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene

1998 • 190 citations

Loss of HLA class I expression in prostate cancer: Implications for immunotherapy

1995 • 189 citations

A reassessment of the role of B7-1 expression in tumor rejection.

1995 • 178 citations

T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.

1994 • 174 citations

Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model

1999 • 170 citations

Deficiency of Transporter for Antigen Presentation (TAP) in Tumor Cells Allows Evasion of Immune Surveillance and Increases Tumorigenesis

1999 • 167 citations

Local and Systemic Therapy of Human Prostate Adenocarcinoma with the Conditionally Replicating Herpes Simplex Virus Vector G207

1999 • 156 citations

Regulation of Telomere Length and Telomerase in T and B Cells

1998 • 154 citations

Telomerase as a universal tumor-associated antigen for cancer immunotherapy

2002 • 152 citations

Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.

2002 • 145 citations

IL-12 regulates VEGF and MMPs in a murine breast cancer model

1998 • 138 citations

Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression.

1994 • 133 citations

Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta.

1999 • 132 citations

Cellular Mucins: Targets for Immunotherapy

2017 • 130 citations

Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene.

1993 • 127 citations

Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer

1998 • 122 citations

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity

1996 • 120 citations

Cationic Liposomes for Direct Gene Transfer in Therapy of Cancer and Other Diseasesa

1994 • 119 citations

Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.

1991 • 114 citations

Adenovirus and adeno-associated virus mediated gene transfer

1995 • 112 citations

Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.

1985 • 110 citations

Telomere Length, Aging, and Somatic Cell Turnover

1999 • 108 citations

Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients

1995 • 103 citations

Cellular Mucins: Targets for Immunotherapy

1994 • 102 citations

Interleukin 2 Gene Therapy for Prostate Cancer: Phase I Clinical Trial and Basic Biology

2001 • 99 citations

Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.

2000 • 99 citations

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

1997 • 99 citations

Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer.

1996 • 99 citations

The Fas/Fas‐ligand system: a mechanism for immune evasion in human breast carcinomas

1999 • 94 citations

Anti‐tumor effects of toxins targeted to the prostate specific membrane antigen

2002 • 92 citations

The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.

1994 • 85 citations

Immunologic approaches to the treatment of prostate cancer.

1999 • 83 citations

Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications

1998 • 83 citations

Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors.

1999 • 76 citations

Detection of the MUC2 apomucin tandem repeat with a mouse monoclonal antibody

1993 • 74 citations

Augmenting the immunogenicity of carbohydrate tumor antigens

1995 • 74 citations

Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer.

1995 • 73 citations

Up-regulation of Fas Ligand at Early Stages and Down-regulation of Fas at Progressed Stages of Intrahepatic Cholangiocarcinoma Reflect Evasion From Immune Surveillance

2000 • 72 citations

Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.

1995 • 70 citations

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

1999 • 69 citations

Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and ⁹⁰yttrium‐DOTA‐peptide‐ChL6

2001 • 69 citations

Fas Ligand Expression in Thyroid Carcinomas: A Potential Mechanism of Immune Evasion

1999 • 64 citations

Gene therapy for human cancer: an essay for clinicians.

1996 • 64 citations

Effect of Canarypox Virus (ALVAC)-Mediated Cytokine Expression on Murine Prostate Tumor Growth

1997 • 63 citations

Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines.

2000 • 60 citations

Gene therapy for prostate cancer.

1999 • 57 citations

A Phase II Study of [⁹⁰Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy

1999 • 55 citations

Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression.

1991 • 55 citations

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.

2001 • 53 citations

Gene delivery and gene therapy with herpes simplex virus-based vectors

2001 • 53 citations

Antiproliferative effect of interferons on human prostate carcinoma cell lines

1989 • 52 citations

Design of a nonviral vector for site‐selective, efficient integration into the human genome

2002 • 49 citations

Infection of the Adrenal Gland as a Route to the Central Nervous System after Viraemia with Herpes Simplex Virus in the Mouse

1986 • 48 citations

Teaching the Immune System to Fight Cancer

1993 • 47 citations

Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy.

2000 • 47 citations

Interferon‐β treatment of metastatic prostate cancer

1986 • 46 citations

Inhibition of cancer cell motility and invasion by interleukin-12

1995 • 46 citations

Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.

1998 • 41 citations

The american journal of pathology-are we there?

1993 • 37 citations

Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach

1999 • 36 citations

Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation

2001 • 35 citations

Defining the Molecular Recognition of MBr1 (Human Breast Cancer) Antigen by the MBr1 Antibody through Probe Structures Prepared by Total Synthesis

1995 • 35 citations

Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center.

1999 • 35 citations

Phase I Pilot Trial of the Bispecific Antibody MDXH210 (anti-FcγRI X anti–HER-2/neu) in Patients Whose Prostate Cancer Overexpresses HER-2/neu

2001 • 35 citations

Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo

1999 • 34 citations

Dendritic cell-based immunotherapy for prostate cancer

1999 • 34 citations

Depletion of the Natural Killer Cell Population in the Peritoneum by AK-5 Tumor Cells Overexpressing Fas-Ligand: A Mechanism of Immune Evasion

1998 • 32 citations

Independent Contributions of GR-1⁺Leukocytes and Fas/FasL Interactions to Induce Apoptosis Following Interleukin-12 Gene Therapy in a Metastatic Model of Prostate Cancer

2001 • 32 citations

Herpes simplex virus hepatitis in macrophage-depleted mice: the role of massive, apoptotic cell death in pathogenesis.

1998 • 30 citations

Inverse Relation of Fas-Ligand and Tumor-Infiltrating Lymphocytes in Angiosarcoma

2001 • 29 citations

Gene therapy of prostate cancer: p53, suicidal genes, and other targets.

1997 • 25 citations

GENE THERAPY FOR PROSTATE CANCER

1999 • 23 citations

Development of gene therapy for prostate cancer using a novel promoter of prostate‐specific antigen

1997 • 23 citations

Ganglioside conjugate vaccines

1994 • 23 citations

Immune recognition of human colonic‐tumour‐associated muc‐2 mucins using an anti‐peptide antibody

1993 • 22 citations

Fas Ligand Expression in Thyroid Carcinomas: A Potential Mechanism of Immune Evasion

1999 • 19 citations

Expansion of Tumor-Infiltrating Lymphocytes from Human Tumors Using the T-Cell Growth Factors Interleukin-2 and Interleukin-4

1993 • 13 citations

Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma

2001 • 13 citations

Telomerase: the search for a universal cancer vaccine

2000 • 11 citations

74 Prostate cancer radiosensitization in vivo with adenovirus-mediated P53 gene therapy

1999 • 10 citations

Trafficking of ‘immune’ CD4+/CD8+ T-lymphocytes into the RENCA tumour microcirculation in vivo in mice

2000 • 8 citations

Leuvectin Vical Inc.

2001 • 8 citations

Intratumoral depot interleukin-2 therapy inhibits tumor growth in Dunning adenocarcinoma of the prostate implanted subcutaneously in rats

1997 • 6 citations

ChemInform Abstract: Defining the Molecular Recognition of Globo H (Human Breast Cancer) Antigen Through Probe Structures Prepared by Total Synthesis.

1996 • 1 citations